A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Asian Subjects With T2DM and Inadequate Glycemic Control on Metformin and Saxagliptin (DS Navigation)
Latest Information Update: 13 Mar 2020
At a glance
- Drugs Dapagliflozin (Primary) ; Metformin; Saxagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 09 Mar 2020 Status changed from recruiting to suspended.
- 14 Aug 2019 Planned End Date changed from 2 Jul 2021 to 1 Nov 2021.
- 14 Aug 2019 Planned primary completion date changed from 2 Jul 2021 to 1 Nov 2021.